Wednesday, December 6, 2023 8:20:47 PM - Markets open
VN-INDEX 1,126.43 +10.46/+0.94%
HNX-INDEX 233.63 +2.29/+0.99%
UPCOM-INDEX 86.31 +0.29/+0.34%
Pharmaceutical stocks remain attractive in 2022 on strong medicine demand
VietNamPlus - 3/11/2022 4:36:37 PM
 (0 ratings. You must sign in to rate.)
As the COVID-19 pandemic continues to spread nationwide and is gradually being considered an endemic disease that could be treated at home, demand for drugs has increased sharply.
Pharmaceutical enterprises are expected to benefit from the situation.
SSI Research expects healthcare demand will recover and grow 13 percent year-on-year in 2022.
“We estimate that domestic health spending will return to normal levels in 2022 as social distancing measures are eased,” SSI wrote in a report for the healthcare industry.
The impact from the pandemic will be less severe and even bring some positive benefits for the pharmaceutical enterprises, it added.
With 70 percent of the Vietnamese population already fully vaccinated with two doses, and new coronavirus variants that may be less dangerous with lower hospitalisation rates, the healthcare demand in 2022 is forecast to soon surpass pre-pandemic levels with hospital visits recovering to normal levels. And the pharmaceutical group will have significant additional revenue from fever reducers and vitamins that are used to treat mild COVID-19 symptoms.
Moreover, many Vietnamese pharmaceutical companies have received formulas for the production of COVID-19 medicines which are transferred by Pfizer and MSD, and may soon be commercialised in 2022.
On February 17, Mekophar Chemical Pharmaceutical JSC (MKP) was licensed by the Ministry of Health to circulate COVID-19 treatment medicine Movinavir with a content of 200mg.
The company’s main markets are in HCM City, accounting for 63 percent, and Hanoi (25 percent), while the rest are other provinces and cities.
Mekorphar is one of three companies licensed to circulate medicine to treat the disease. The other two companies are Stellapharm Joint Venture Company Limited and Boston Vietnam Pharmaceutical JSC.
According to SSI’s report, profits for healthcare companies are likely to grow strongly in 2022, with prices for medical services and medicines expected to rise slightly.
“We estimate healthcare companies' profits to grow 15 percent year-on-year, driven by 12 percent revenue growth and an expected 4-6 percent increase in prices for both medicine and medical services,” said SSI.
“The price increase is inevitable as pharmaceutical companies have had to cope with higher prices of raw materials, while hospitals have faced many expensive operating costs in the past two years during the outbreak of COVID-19.”
Traphaco JSC (TRA) is not a manufacturer or distributor of medicine to treat COVID-19 but attracts investors with the advantage of producing product lines to support coronavirus treatment such as saline solution, T-B antibacterial mouthwash and medicine to enhance immunity to protect lungs and nasal drops.
The Phu Hung Securities Corporation believes that Traphaco will continue to maintain its number one position in the traditional medicine industry, focusing on investing in developing traditional medicines as growth momentum in the new period.
The advantage of Traphaco is the extensive distribution system throughout the country and high brand awareness that will help TRA maintain the advantage of traditional medicines on the over the counter (OTC) channel.
Currently, the company has more than 27,000 customers with 28 branches nationwide.
Therefore, pharmaceutical companies are expected to record high growth for the whole of 2022, while the hospital group will achieve high growth in the second half of the year, SSI said. 
“For pharmaceutical companies, we believe that business results may be positive in the first half of 2022, as people stockpile medicine for the new Omicron variant of COVID-19, while the group of hospitals must wait for a recovery in the second half of this year, when Vietnam can cope with the new variant and ease travel restrictions,” the securities firm added.
On the stock market, with the positive profit growth prospect, SSI expects stocks of pharmaceutical companies continue to be attractive during the pandemic period.
Le Xuan, a senior trader, said that pharmaceutical stocks are defensive stocks, as they are not affected by macro factors, but by people's demand for health examination and treatment.
"In 2022, the industry's potential is quite good thanks to rising demand for health check and treatment," said Xuan./.
Read original article here
Newer News
10:15 Market little changed as liquidity slows down
05/12 Strong return of liquidity lifts market's sentiment
04/12 New circular aims to improve stock market transparency
01/12 Gov’t to tighten oversight of banking, securities following recent scandals
28/11 Low bank rates fail to stimulate strong capital influx into securities market
25/11 Market snaps three-day winning streak on unexpected selling pressure
25/11 Market ends week on a positive note
25/11 Ministry of Finance issues Circular 69 for reorganisation of securities market
22/11 Shares extend gains but liquidity stays low
14/11 Policy changes required to provide a boost to property sector
Older News
03/03 Real estate, securities markets expected to continue to grow in 2022
02/03 Large-cap recovery boosts VN-Index close to 1,500 points
28/02 Investors show sentimental value in stocks
28/02 Shares to move sideways before returning to uptrend
23/02 Tourism stocks expected to shine in 2022
15/02 Market extends losses on bank stocks, VN-Index loses nearly 30 points
15/02 No more easy money flow and wild expectations in 2022: SGI Capital
10/02 HOSE to put KRX trading system into operation this year
08/02 VN-Index inches closer to 1,500 points after Tết holidays
07/02 Bank stocks expect a promising year in 2022: experts
Newsletter Signup
Top Stories
Hà Nội’s CPI rises 4.72% in 11 months
Gov’t to tighten oversight of banking, securities following recent scandals
Banks increase capital through paying dividends in shares
VN-Index loses nearly 11 per cent in October
Market's recovery momentum remains, but facing supply pressure
Market Update
Last updated at 3:05:01 PM
VN-INDEX 1,126.43 +10.46/+0.94%
Real-time chart
Top 5 Actives
Top 5 Gainers
Top 5 Losers
My Favorite Quotes
Your most recently viewed tickers will automatically show up here if you type a ticker in the Get Quotes box on the top of the page.
Company Research
Type in the symbol above for thorough background information, key statistics and financial information.
Stock Sectors
We continuously improve our services, here are the latest updates...
Allow you to monitor a customised group of securities. You can set up multiple Portfolios to help you better manage your investments.
Trigger Alerts
Get up-to-date alerts delivered directly to your email address.
Stock Screener
Allow you to filter the market and find exactly what sort of company you are looking for.
Live Terminal
Get instant access to FREE REAL-TIME streaming quotes for hundreds of stocks from HOSE, HNX and UPCOM exchanges.